EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Case for Synthetic Data in Regulatory Decision‐Making in Europe

Clara Alloza iD, Bethany Knox iD, Hanaya Raad iD, Mireia Aguilà iD, Ciara Coakley iD, Zuzana Mohrova iD, Élodie Boin iD, Marc Bénard, Jessica Davies, Emmanuelle Jacquot, Coralie Lecomte iD, Alban Fabre und 1 weitere

Clinical Pharmacology & Therapeutics · 2023-10 · 114 (4) · 795-801

DOI: 10.1002/cpt.3001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 24.08.2023. Verfasst von Clara Alloza und 12 weiteren Autor:innen. Beteiligte Einrichtung: Aetion, Inc., New York, New York, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Technology Assessment, Biomedical. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regulators are faced with many challenges surrounding health data usage, including privacy, fragmentation, validity, and generalizability, especially in the European Union, for which synthetic data may provide innovative solutions. Synthetic data, defined as data artificially generated rather than captured in the real world, are increasingly being used for healthcare research purposes as a proxy to real‐world data (RWD). Currently, there are barriers particularly challenging in Europe, where sharing patient's data is strictly regulated, costly, and time‐consuming, causing delays in evidence generation and regulatory approvals. Recent initiatives are encouraging the use of synthetic data in regulatory decision making and health technology assessment to overcome these challenges, but synthetic data have still to overcome realistic obstacles before their adoption by researchers and regulators in Europe. Thus, the emerging use of RWD and synthetic data by pharmaceutical and medical device industries calls regulatory bodies to provide a framework for proper evidence generation and informed regulatory decision making. As the provision of data becomes more ubiquitous in scientific research, so will innovations in artificial intelligence, machine learning, and generation of synthetic data, making the exploration and intricacies of this topic all the more important and timely. In this review, we discuss the potential merits and challenges of synthetic data in the context of decision making in the European regulatory environment. We explore the current uses of synthetic data and ongoing initiatives, the value of synthetic data for regulatory purposes, and realistic barriers to the adoption of synthetic data in healthcare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceTechnology Assessment, BiomedicalHumansEuropeEuropean Union

Autor:innen und Institutionen

  • Aetion, Inc., New York, New York, USA.

ORCID-Profile: Clara Alloza, Bethany Knox, Hanaya Raad, Mireia Aguilà, Ciara Coakley, Zuzana Mohrova, Élodie Boin, Coralie Lecomte, Michael Batech

Zitieren

APA

Alloza, C., Knox, B., Raad, H., Aguilà, M., Coakley, C., Mohrova, Z., Boin, É., Bénard, M., Davies, J., Jacquot, E., Lecomte, C., Fabre, A., & Batech, M. (2023). A Case for Synthetic Data in Regulatory Decision‐Making in Europe. Clinical Pharmacology & Therapeutics, 114(4), 795-801. https://doi.org/10.1002/cpt.3001

Vancouver

Alloza C, Knox B, Raad H, Aguilà M, Coakley C, Mohrova Z, et al. A Case for Synthetic Data in Regulatory Decision‐Making in Europe. Clinical Pharmacology & Therapeutics. 2023;114(4):795-801. doi:10.1002/cpt.3001

BibTeX
@article{Alloza2023,
  author = {Alloza, Clara and Knox, Bethany and Raad, Hanaya and Aguilà, Mireia and Coakley, Ciara and Mohrova, Zuzana and Boin, Élodie and Bénard, Marc and Davies, Jessica and Jacquot, Emmanuelle and Lecomte, Coralie and Fabre, Alban and Batech, Michael},
  title = {A Case for Synthetic Data in Regulatory Decision‐Making in Europe},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {4},
  pages = {795--801},
  doi = {10.1002/cpt.3001}
}
Kostenlos starten →